Donate
Stopping Cancer Early – The Best Possible Investment

Tweets

    Blog

    Archive for the ‘Canary Challenge’ Category

    Canary Foundation Welcomes Dr. Joseph DeSimone

    November 22, 2020

    Dr. Joseph DeSimone

    We welcome Professor Joseph M. DeSimone, PhD. in the position of the Sanjiv Sam Gambhir Professor in Translational Medicine. We are fortunate to have such creative and capable leadership as our work together in cancer early detection continues.

    From the Stanford Press Release: The Stanford Department of Radiology is proud to announce Professor Joseph M. DeSimone as the inaugural Sanjiv Sam Gambhir Professor in Translational Medicine. A shining example of achievement, Joe has been described as “an igniter of innovation”. He has received international recognition as a scientist, inventor, and entrepreneur, earning major accolades including the U.S. Presidential Green Chemistry Challenge Award, the 2017 Heinz Award, and the Lemelson-MIT Prize. He is one of only 25 individuals elected to all three U.S. National Academies—the National Academy of Sciences, Medicine, and Engineering. In 2016, President Obama presented him with the National Medal of Technology and Innovation, the highest honor in the U.S. for achievement and leadership in advancing technological progress. Read more here.

    Joe and his lab have made significant scientific breakthroughs in science and medicine including next-generation approaches to cancer treatment and diagnosis, implantable drug delivery devices, green chemistry, and most recently in 3D printing technology for medical devices tailored to an individual patient’s needs. A dedicated educator and strong advocate for bringing a broader diversity of perspectives into research, he has mentored over 80 students through PhD completion at Univ. of North Carolina and North Carolina State Univ. (his former 30-year career), half of whom were women and members of underrepresented groups in STEM.

    As an avid researcher and innovator, Joe has authored over 370 scientific publications with over 42,000 citations to his work, and is a named inventor on over 200 issued patents. Additionally, he brings a unique ability to transfer novel solutions from his lab to the world through the companies he co-founded.

     

     

     

    Project Baseline aims to map human health

    February 3, 2019

    What if we could view changes in the body earlier than early to warn of possible disease? That is the aim of Project Baseline, to map human health. The New York Times published “Project Baseline Aims to Ward Off Illness Before We Get Sick” by Anahad O’Connor (Oct 2018).  The study is recruiting 10,000 adults. And each will be examined and followed for at least four years. So the goal is to discover the earliest warning signs of cancer, heart disease and other killers. Participants, the first of whom was enrolled in 2017, are called Baseline Explorers.

    Project Baseline is the result of conversations in 2013, led by Google X’s Andrew Conrad. He consulted with Dr. Sam Gambhir, MD, chair of Radiology at Stanford University and director of the Canary Center for Cancer Early Detection. And also with Robert M. Califf, MD, professor of Cardiology in the School of Medicine, Duke University.

    Conrad (now CEO of Verily, a spin out of Google X) was interested in exploring with these two notable healthcare thought leaders, one in cancer and the other in cardiology, about how to create what has become a landmark study. Both had deep experience in working with large patient cohorts and focus on early detection of disease. The project has formed teams across the country.

    Seeking to create a baseline of health

    Traditional trials focus on those who have a disease. So Project Baseline, as the name implies, mainly enrolls healthy individuals gathering enormous amounts of information. Baseline equips enrollees with wearable technology from Verily that tracks sleep patterns, heart rhythms and physical activity. The team is developing tools and technologies to collect, organize, analyze and curate the data.

    And investigators are determining the best ways to share data with participants that is helpful to them. They are looking at how they can engage with their medical professionals.

    Canary Foundation and the Canary Center at Stanford for Cancer Early Detection

    Dr. Gambhir has served as Canary Foundation’s scientific director for more than a decade. He led the development of the Canary Center at Stanford for Cancer Early Detection.  The Canary Center is a partnership forged in 2008 between Stanford University and Canary Foundation under the leadership of Don Listwin, based on the foundation’s mission. And interesting to know,  Canary Center is the first program Stanford has focused entirely on cancer early detection.

     

    Cycling for Canary – one rider’s drive

    June 13, 2016

    Nitish Amin is a 3-time Canary Challenge participant and is currently gearing up for his fourth Challenge, riding with team Cisco. In this guest blog he reflects on his love of biking and passion for supporting cancer early detection.

    Growing up in India, I biked everywhere, every day, as a child.

    I grew up, as we all do, moved to the United States and set biking aside. However, three years ago, I started biking again.

    Nitish3-768x457The first time I got on my Cannonade (that’s a really great bike, if you don’t know) something just felt right. I have that feeling when I get on the saddle every Sunday morning.

    I see more when I’m on my bike than when I’m in a car. I usually take the roads and routes that I haven’t explored. It is an amazing hobby that allows me to slow down, even when I’m going 20+ miles per hour. I stop to talk to people. For the next few hours that I’m on my bike, it’s just me, nature, and my fellow biking enthusiasts. I am always amazed at how new many friends I make see when I’m riding. These friends I made, we call ourselves, “CRANK OF DAWN” because we like to ride early.

    It’s the same during my 8+ years at Cisco, where I get to see how many great people I work with. I am a Software Technology Manager and while we’re all moving fast to innovate and to change the world, when we take a moment to slow down, enjoy what we do, we get to see a little more, take a few unexplored paths, and just talk to each other. We also have time to give back together.

    I learned about the Canary Foundation through Cisco’s volunteer program. It is the non-profit organization dedicated solely to the funding, discovery and development of tests for early cancer detection. This photo of me is during a 50-mile ride for the Canary Challenge. I like that Cisco encourages us to give back in ways that are personal to us, and in our local communities.

    My father started one of the first early cancer detection centers back in the 1970s in Gujarat, India. When I ride for Canary, I feel that sense of connection between where I am now, at Cisco, and where I came from, all while contributing to a worthy cause.

    Team Vanderkitten Partners with the Canary Challenge for the Third Year in a Row

    March 18, 2014

    The Canary Challenge has partnered with pro women’s cycling team, Team Vanderkitten for the third year in a row. The Vanderkittens are sponsoring the Canary Challenge ride on September 27, 2014, which benefits the Canary Center at Stanford for Early Cancer Detection.

    Team Vanderkitten is a professional women’s cycling team that competes in major women’s cycling events around the world.

    The Vanderkittens kicked off this year’s sponsorship of the Canary Challenge by holding an exclusive training ride, which met at the all-new Canary Center at Stanford For Early Cancer Detection in Palo Alto, California. The Canary Center is a state of the art research center that employs teams of scientists in the field of early cancer detection research.

    Vanderkitten Team Director, Jono Coulter, “This is our 3rd year with the Canary Challenge. We’re bringing riders from all over the world: Australia, New Zealand, and Canada, to come and ride this event. Early cancer detection is super important to this community and we want to bring a lot of riders out to take advantage of the wonderful riding in Northern California and raise money for the Canary Foundation.”

    The Vanderkittens, alongside Vanderkitten VIP riders, and Canary Challenge Team Captains, enjoyed a stunning ride that climbed through the hills of the Bay Area Peninsula and up the famous Kings Mountain climb which will be part of the course for the Canary Challenge on September 27, 2014.

    Vanderkitten VIPs are ambassadors of the Vanderkitten brand and leading women in the outdoor lifestyle world. After the ride, the group enjoyed lunch, a tour of the Canary Center, and a presentation on early cancer detection research from Canary Foundation Executive Director, Ronica Sanders Smucker.

    Canary Foundation is the world’s first non-profit organization dedicated solely to the funding, discovery, and development of tests for early cancer detection. They are the host and beneficiary of the upcoming annual Canary Challenge, a fundraiser bike ride that starts and finishes from the HP headquarters in Palo Alto. In 2013, the Canary Challenge raised over $800,000 for early cancer detection research, achieved by over 800 participants.

    The Canary Challenge in 2014 aims to raise $1.25 million with 1500 riders. The Canary Challenge is the premier single day cycling fundraiser in the San Francisco Bay Area, touting rest stops featuring gourmet food, full support, and a family-friendly after party at the finish line.

    The Canary Challenge is on September 27, 2014 and features 5 routes, ranging from 5k to 100mi. To sign up, visit www.CanaryChallenge.com.

    Upwards and Onwards: Canary Goals for 2014

    January 29, 2014

    The beginning of the year presents a cue to reflect on the successes of the previous year, and look forward to goals for the coming months. We’re delighted to announce progress with our research that has tremendous implications for future innovations, as well as our ambitions for the Canary Challenge 2014.

    slide

    New technologies always evoke excitement and anticipation. Here at Canary, if a scientist wants to use a new technology to advance or improve the ways we detect cancer tumors early, we are all for it. Enhanced ultrasound using microbubble technology is one of these technologies.

    This technology will change the way doctors view tumors. Microbubbles are miniature gas bubbles, mostly containing oxygen or air, which can be uniformly suspended in a liquid such as blood. Due to their size, they can pass through even the smallest of blood vessels and therefore are commonly used together with medical ultrasound imaging. As effective vehicles for highlighting blood in ultrasound images, Canary scientists use microbubbles as a contrast agent to view cancer tumors. Our clinical trials in Rome with women who have ovarian cancer have produced great results. Here in the US, we anticipate replicating microbubble technology for applications with breast cancer, prostate and pancreatic cancer.

    We also value and actively seek out key partnerships, whether academic or industry. Soon we’ll announce a partnership with Genomic Health Inc. in the area of prostate cancer. We’re in talks with MD Anderson in Houston to help with coordinating a national multi-institutional lung cancer study.

    We have great plans for our largest fundraising event, the Canary Challenge, which is about to get bigger and better than ever. Mark your calendar now for September 27, 2014. Register now for $25 until March 31. The event will be hosted at HP’s campus in Palo Alto on Hanover St. We’re aiming high this year with a goal of raising $1.5 million, recruiting 150 teams and over 1,500 riders. This year’s ride will benefit the Canary Center at Stanford, supporting the researchers, scientists and doctors who are dedicated to cancer early detection. Come be a part of an amazing one-day cycling event!

    We’re pleased to announce that we will again be partnering with women’s pro cycling team extraordinaire, the Vanderkittens, who will host monthly training rides for Canary Challenge riders. Hani Juha, a cyclist and great coach, of Menlo Bike Club will also offer weekly training rides, an annual training program, as well as monthly clinics. We invite anyone and everyone in the Canary community to take advantage of these tailored experiences to brush up on their skills in time for the event.

    What are your hopes and dreams for cancer early detection research at Canary Foundation? Let us know in the comments below!

    What’s it Like to Ride the Canary Challenge?

    December 16, 2013

    Save the date to register for the Canary Challenge 2014- registration opens on January 4 in the New Year!

     

    Canary Highpoints: Cancer Early Detection Research Progress 2013

    December 4, 2013

    Canary Foundation’s progress continues to be on a rapid path. Through prestigious partnerships, research, and clinical trials with quantifiable results, Canary Foundation is funding early detection research that will save lives and permanently change the landscape of cancer diagnostics. People like you have made this progress possible.

    In 2013, our partnership with Stanford University expanded and we moved into our new state-of-the-art Canary Center at Stanford to continue our work realizing early detection solutions.

    We are pleased to share a new video featuring our high points. We thought this was a great way to reflect on key ideas Canary was founded upon that have become reality. We invite you to view our 5-minute Canary Foundation video!

    When you and your family make giving decisions this holiday, we ask that make cancer early detection a priority. Please give generously.

    Prostate Cancer Early Detection: Canary PASS Trial Hits Important Milestone

    November 14, 2013

    About one man in six will be diagnosed with prostate cancer in his lifetime. Most men diagnosed with prostate cancer will not die from it. With screening, we’re doing better at identifying prostate cancer early. But now, the clinical question is: with a prostate cancer diagnosis, do we treat, or is treatment not necessary?

    ProstateTreating prostate cancer when it’s not necessary exposes men to potential side effects—including incontinence and impotence– of aggressive treatment like surgery. This is known as overtreatment. We need better tools to differentiate aggressive prostate cancer from non-aggressive prostate cancer to guide these decisions.

    In 2007, the Canary prostate team decided to focus on this important clinical question. How will we distinguish lethal from non-lethal prostate cancer? Identifying the difference early on will save lives. New tools will also help end unnecessary biopsies and overtreatment.

    By 2008, the team launched a clinical trial called PASS, the Prostate Active Surveillance Study. Men with early stage, localized, low-risk prostate cancer can enroll and have their cancer closely monitored for signs of progression. This process is called active surveillance. The trial’s goal is to manage low-risk prostate cancer through active surveillance while identifying markers to distinguish non-aggressive prostate cancer from potentially lethal disease.

    The PASS trial has been running smoothly, and in October 2013, the PASS Trial reached another major milestone when the 1,000th man was enrolled in the trial.

    We are so grateful for Canary Foundation supporters, who provided funding early on for this work. They recognized that the project was underfunded and important. We’re also extremely thankful to the men who participated in the trial for contributing tens of thousands of samples to prostate cancer early detection research. Thank you!

    Lung Cancer Early Detection: Canary Foundation Collaborates with MD Anderson

    November 7, 2013

    Recently, Canary Foundation and Stanford embarked on a collaboration with the MD Anderson Cancer Center, working together on a large-scale initiative to improve the screening process of lung cancer for earlier detection of this lethal disease.

    MDACC_RGB_TC_tag_VThe Canary lung cancer team leader, Dr. Sam Hanash, was recruited to the MD Anderson Cancer Center, which launched an ambitious Moon Shots Program aimed at rapidly and significantly reducing mortality in several major cancers. Lung cancer is currently the leading cause of cancer deaths.

    As part of Moon Shots program, lung cancer physicians and researchers are initiating a screening study to improve screening for lung cancer. The goal is to recruit 10,000 individuals in the U.S., and to partner with international sites, including China and Germany, to conduct studies with an additional 10,000 patients. Canary will be joining forces with MD Anderson, combining CT scan technology and biomarker research to better interpret screening results.

    These clinical trials represent the next phase of Canary research, taking the progress we’ve made in the lab and testing it in a larger clinical setting.

    Canary Awards for Outstanding Early Cancer Detection Research

    October 29, 2013

    Each year, Canary Awards — often featuring a golden or crystal canary — are presented at the Canary Symposium to recognize the year’s outstanding contributions. This year, two awards were bestowed for teams who demonstrated outstanding progress in their cancer early detection research.
    Prostate

    Photo: The clinical trial coordinators for the Canary Prostate Active Surveillance Study (PASS) accept the 2013 Canary Award on behalf of the Canary Prostate Team.

    Dr. Dianne Miller was presented with the award for her team’s success in promoting adoption of ovarian cancer prevention programs throughout the Canadian province of British Columbia. Because lethal ovarian cancer often originates in fallopian tubes, their removal can prevent the development of ovarian cancer, potentially reducing the incidence by 50% or more. Since the advent of the British Columbia educational campaign in September 2010, clinics across the province have seen a practice shift toward removal of fallopian tubes during common gynecological surgeries (such as hysterectomy and tubal ligation), thanks to the efforts of Dr. Miller’s team.

    The Canary Prostate team was presented with the Canary Award for the team’s success in meeting or exceeding all of its major milestones in the Prostate Active Surveillance Study (PASS) clinical trial. Earlier in the month of October, 2013, the PASS trial celebrated reaching another major milestone, as the 1,000th participant was enrolled in the trial. The trial’s goal is to manage low-risk prostate cancer through active surveillance while identifying markers to distinguish non-aggressive prostate cancer from potentially lethal disease.

    Congratulations to both teams for all their hard work, and to all the Canary teams who work tirelessly to develop research and solutions to make accessible cancer early detection a reality.

    Tweets